In addition to miR-34a-5p, we have found that SIRT1 is also a target of miR-26b-5p, and its protein expression might have corresponded with a synergistic effect, although miR-26b-5p has not yet been described as a NAFLD mediator, unlike its family member, miR-26a (Ali et al., 2018; Xu et al., 2021a,b). The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.